https://www.thebodypro.com/author/polly-clayden

Latest by Polly Clayden

No Effect of Tenofovir on Infant Bone Mineral Content in African Study Img
CROI (Conference on Retroviruses and Opportunistic Infections)

No Effect of Tenofovir on Infant Bone Mineral Content in African Study

A report from the PROMISE study showed no adverse bone mineral effect, linked to maternal tenofovir disoproxil fumarate (TDF), in exposed infants.

Use of Modelling to Predict Pediatric Dosing of Long-Acting Antiretrovirals Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Use of Modelling to Predict Pediatric Dosing of Long-Acting Antiretrovirals

Physiologically based pharmacokinetic modeling can help predict dosing strategies for long-acting antiretrovirals, according to data presented at CROI 2016.

Nevirapine Dosing for Treatment of Neonates Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Nevirapine Dosing for Treatment of Neonates

Population modelling and pharmacokinetic simulations shown at CROI 2016 predicted dosing regimens to achieve target nevirapine treatment concentrations in term and late preterm infants.

Doravirine Can Be Co-Administered With Oral Contraceptives Img

Doravirine Can Be Co-Administered With Oral Contraceptives

Multiple dosing with doravirine does not change the plasma pharmacokinetics of a single dose of ethinyl estradiol or levonorgestrel to a clinically important extent, according to data shown at the 6th International Workshop on HIV and Women.

No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry Img

No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry

The Antiretroviral Pregnancy Registry found no apparent increase in the frequency of specific birth defects with first trimester darunavir exposure.

Timeline for Access to Generic Dolutegravir: What Still Needs to Be Done Img
News

Timeline for Access to Generic Dolutegravir: What Still Needs to Be Done

Dolutegravir (DTG) is widely predicted to both provide better antiretroviral options for low-income countries and reduce the cost of global ART. But a number of steps need to happen before DTG is widely available and recommended for all populations....

Countries With Lower HIV Prevalence Have Lower Treatment Coverage Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Countries With Lower HIV Prevalence Have Lower Treatment Coverage

Low- and middle-income countries with adult HIV prevalence less than 5% had significantly lower rates of treatment coverage in adults, pregnant women and children than those with higher prevalence.

Dolutegravir: 48-Week Results in Children Age 6 to 12 Years Old Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Dolutegravir: 48-Week Results in Children Age 6 to 12 Years Old

Dolutegravir is safe and effective in children age 6-12 years, according to results presented at CROI 2016.

New Antiretrovirals Could Mean Savings Up to $3 Billion by 2025 Img
CROI (Conference on Retroviruses and Opportunistic Infections)

New Antiretrovirals Could Mean Savings Up to $3 Billion by 2025

The introduction of three new antiretrovirals into treatment programmes in low- and middle-income countries -- tenofovir alafenamide fumarate (TAF), low-dose efavirenz (Sustiva, Stocrin) and dolutegravir (Tivicay, DTG) -- could represent over $3 bill...

Large Variation Across Countries in Meeting UNAIDS 90-90-90 Targets Img
IAS (International AIDS Society) Conference

Large Variation Across Countries in Meeting UNAIDS 90-90-90 Targets

Analysis of national treatment cascades showed huge variation in achieving UNAIDS 90-90-90 targets. The proportion of HIV positive people with undetectable viral load ranged from 68% in Switzerland to 9% in Russia. No country analysed met the UNAIDS ...